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Abstract
Background
Invasive fungal disease (IFD) causes significant morbidity and mortality in hematologic
malignancy patients with high-risk febrile neutropenia (FN). These patients therefore often
receive empirical antifungal therapy. Diagnostic test-guided pre-emptive antifungal therapy
has been evaluated as an alternative treatment strategy in these patients.
Methods
We conducted an electronic search for literature comparing empirical versus pre-emptive
antifungal strategies in FN among adult hematologic malignancy patients. We systemati-
cally reviewed 9 studies, including randomized-controlled trials, cohort studies, and feasibil-
ity studies. Random and fixed-effect models were used to generate pooled relative risk
estimates of IFD detection, IFD-related mortality, overall mortality, and rates and duration of
antifungal therapy. Heterogeneity was measured via Cochran’s Q test, I2 statistic, and
between study τ2. Incorporating these parameters and direct costs of drugs and diagnostic
testing, we constructed a comparative costing model for the two strategies. We conducted
probabilistic sensitivity analysis on pooled estimates and one-way sensitivity analyses on
other key parameters with uncertain estimates.
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Results
Nine published studies met inclusion criteria. Compared to empirical antifungal therapy,
pre-emptive strategies were associated with significantly lower antifungal exposure (RR
0.48, 95% CI 0.27–0.85) and duration without an increase in IFD-related mortality (RR 0.82,
95% CI 0.36–1.87) or overall mortality (RR 0.95, 95% CI 0.46–1.99). The pre-emptive strat-
egy cost $324 less (95% credible interval -$291.88 to $418.65 pre-emptive compared to
empirical) than the empirical approach per FN episode. However, the cost difference was
influenced by relatively small changes in costs of antifungal therapy and diagnostic testing.
Conclusions
Compared to empirical antifungal therapy, pre-emptive antifungal therapy in patients with
high-risk FN may decrease antifungal use without increasing mortality. We demonstrate a
state of economic equipoise between empirical and diagnostic-directed pre-emptive anti-
fungal treatment strategies, influenced by small changes in cost of antifungal therapy and
diagnostic testing, in the current literature. This work emphasizes the need for optimization
of existing fungal diagnostic strategies, development of more efficient diagnostic strategies,
and less toxic and more cost-effective antifungals.
Introduction
Invasive fungal disease (IFD) is an important cause of morbidity and death in hematologic
malignancy or hematopoietic stem-cell transplantation (HSCT) patients with high-risk febrile
neutropenia (FN) [1–6]. These infections confer a substantial economic burden due to
increased hospital stays and drug costs [7,8].
Prompt initiation of appropriate antifungal therapy early in the course of IFD reduces IFD-
related mortality. Because of the consequences of not treating IFD early and limitations in
existing IFD diagnostic methods, many patients with high-risk neutropenia and persistent or
recurrent fevers despite broad-spectrum antibiotic therapy receive empiric antifungal therapy
[4,9].
Early IFD diagnosis remains challenging because of the low sensitivity and specificity of
clinical symptoms, microbiological cultures, and radiologic tools for IFD. Non-culture-based
techniques have been developed to identify Aspergillus species and other fungi, including detec-
tion of circulating Aspergillus galactomannan [10–12] and fungal (1!3)-β-D-glucan antigens
[13–15], and polymerase chain reaction (PCR) assays targeting Aspergillus nucleic acid
sequences [16]. These tests, in conjunction with high-resolution chest computed tomography
(CT), are frequently used to diagnose IFD in patients with high-risk FN [17,18].
Given these developments in IFD diagnostic testing and the toxicity and costs of prolonged
antifungal exposure, diagnostic test-guided pre-emptive antifungal therapy has been evaluated
as an alternative strategy to empirical antifungal therapy. Reserving antifungal therapy for the
subset of patients who have early evidence of IFD by careful clinical assessments and serial fun-
gal biomarker evaluations might reduce antifungal drug use and its attendant toxicity and costs
without increasing IFD-related morbidity or mortality.
Studies of varying design have evaluated the feasibility and clinical effectiveness of empirical
and pre-emptive approaches for antifungal therapy in FN patients [19–23]. Here, we use a sys-
tematic approach to summarize the existing literature on IFD outcomes and antifungal use
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with empirical versus pre-emptive antifungal strategies in hematologic malignancy and HSCT
patients with high-risk FN, and incorporate these data into a decision analysis model to com-
pare the relative economic burden of these two strategies.
Methods
Systematic Review/Meta-Analysis
We searched electronically for published or publicly presented scientific literature comparing
empirical and pre-emptive strategies for treating adult hematology patients with high-risk FN
[9]. Using PubMed, we searched for combinations of terms including “invasive fungal disease,”
“hematologic malignancy,” “pre-emptive,” “diagnostic-directed,” “febrile neutropenia,” and
“antifungal” to find published literature from January 1990 to June 2015. A manual search of
the reference lists of select articles was also conducted. We searched for abstracts from major
scientific meetings, including the Interscience Conference on Antimicrobial Agents and Che-
motherapy, Infectious Diseases Week Conference, and the Infectious Disease Society of Amer-
ica (IDSA), American Society of Clinical Oncology, and American Society of Hematology
Annual Meetings. For conference abstracts meeting our search criteria, posters or presentations
were reviewed to facilitate data abstraction. This study is not included in a systematic review
registry.
Data were extracted independently by primary researchers, and cross-checked by other
investigators. Outcomes measured included IFD detection, IFD-related mortality, and rates of
“pre-IFD diagnosis” empirical antifungal therapy, defined as antifungal therapy administered
prior to the start of treatment for incident probable or proven IFD [24]. When these outcomes
were not explicitly reported in the primary literature, we calculated these parameters using
reported data. We used Mantel-Haenszel (M-H) fixed-effects and Dersimonian-Laird (D-L)
random effects models to generate pooled estimates of outcomes, represented as relative risks
(RR) and 95% confidence intervals (95% CI) comparing pre-emptive to empirical strategies.
We assessed heterogeneity by calculating Cochran's Q, I-squared, and the between-study
variance tau-squared. Bias was assessed at the study level. Specifically, we used the Cochrane
Collaboration’s “Risk of Bias” tool to assess bias in randomized controlled studies and the New-
castle-Ottawa Scale to assess for risk of biased in non-randomized studies. As observational
studies are at higher risk of being biased, a restricted analysis was conducted, only including
more robust randomized-controlled studies. All statistical analyses were conducted using Stata
13 software.
Cost Comparison
We created a decision tree model (TreeAgePro 2015, TreeAge Software, Inc, Williamstown,
MA) and conducted a cost analysis comparing two strategies for antifungal therapy among
neutropenic patients with hematologic malignancy or HSCT at high risk for IFD: (1) an empir-
ical (fever-directed) approach, in which patients febrile after 4 days of broad-spectrum antibi-
otics start empirical antifungals [9], and (2) a pre-emptive (diagnostic test-based) approach, in
which patients start pre-emptive antifungal therapy if they develop a positive serum galacto-
mannan test and pneumonia on chest imaging. Patients in both groups receive subsequent
treatment antifungals if they develop incident proven or probable IFD [24]. Specifically, we
report the incremental cost difference (in 2014 U.S. dollars) of pre-emptive versus empirical
treatment strategies per patient with a prolonged FN episode (starting at>4 days) for (a) the
pre-emptive or empirical period alone and (b) the overall treatment period, including treat-
ment of incident proven or probable IFD.
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Fig 1 shows the structure of our cost comparison model. Based on our meta-analysis, we
assumed no difference in overall IFD-related morbidity or mortality between the groups. We
also assumed no difference in the diagnostic testing strategy but did assume a difference in the
detection and duration of pre-emptive versus empirical antifungal use prior to diagnosis of
incident IFD (based on pooled RR estimates from our meta-analysis).
Based on our systematic review and meta-analysis, the diagnostic testing strategy in both
groups consisted of two serum galactomannan tests per week of FN beyond 4 days and one
high-resolution chest CT per FN episode. Base case diagnostic testing assumptions factored in
the reality that many empirical strategies incorporate diagnostic testing [20]. Neutropenia
duration was assumed to be 18 days in both groups [25–28], with initiation of either empirical
or pre-emptive antifungal therapy after the first 4 days.
Antifungal agents in patients with proven or probable IFD, according to 2008 European
Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG)
consensus definitions [24], were assumed to be the same in the two groups. The base case
choice and distribution of antifungal agents for empirical and pre-emptive therapy and for
treatment of proven or probable IFD were defined by IDSA treatment guidelines for treatment
of invasive aspergillosis [4,9] and by a group of Infectious Diseases physicians and clinical
pharmacists with expertise in caring for hematology and HSCT patients with FN at Brigham
andWomen’s Hospital and Dana-Farber Cancer Institute. The duration of treatment for inci-
dent IFD was defined as 12 weeks (84 days) [4,9]. Importantly, toxicity was not incorporated
into this model given evidence from our systematic review showing no significant difference in
amphotericin, echinocandin, or azole-related renal or hepatic toxicity between patients receiv-
ing antifungal therapy on an empirical or pre-emptive basis [29,30].
Fig 1. Cost comparisonmodel of empirical versus pre-emptive antifungal therapy in high-risk neutropenic patients.
doi:10.1371/journal.pone.0140930.g001
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Otherwise, per the randomized trials in our systematic review [26,31], baseline characteris-
tics of the two antifungal therapy groups—age, gender, oncologic diagnosis, and phase of ther-
apy (induction, relapse, consolidation, and transplantation)—were assumed to be similar. We
also assumed healthcare utilization and health outcomes of the two groups beyond specified
differences in the antifungal therapeutic strategy and measured clinical outcomes were similar.
Direct costs for diagnostic imaging were derived from a publicly-available database on
health care costs [32]. The cost of serum galactomannan testing was derived from the Brigham
andWomen’s Hospital and Dana-Farber Cancer Institute laboratory costs. Antifungal drug
costs were based on average wholesale price from the Red Book [32].
We conducted a probabilistic sensitivity analysis (second-order Monte Carlo simulation)
with 10,000 simulations and lognormal distributions on pooled RR estimates in our model to
calculate 95% credible intervals for the incremental cost difference between pre-emptive and
empirical antifungal strategies. We also conducted best- and worst-case analyses around diag-
nostic testing strategy and antifungal drug costs (using the least and most costly antifungal
agents). Finally, we conducted sensitivity analyses using only parameters derived from large
randomized controlled trials of empirical versus preemptive antifungal strategies.
Results
Systematic Review/Meta-Analysis
Our initial query returned 172 studies. Of these, ten published articles met our inclusion crite-
ria, presenting primary literature comparing empirical and pre-emptive antifungal treatment
strategy in hematologic malignancy or HSCT patients with high-risk FN. One study was fur-
ther excluded due to uncertainty about data quality (Fig 2). Two presentations from infectious
diseases and mycology conferences met our inclusion criteria, but both corresponded with one
of the ten published articles [26,28]. Table 1 summarizes the design of these studies and Tables
2 and 3 summarize the meta-analysis results of these reports [26,28–31,34–37].
Of the nine reports meeting our inclusion criteria, five were randomized trials, two were
prospective feasibility studies, one was a prospective interventional study, and one was a retro-
spective cohort study. Studies were published or presented between 2005–2013, with data col-
lected from 1998–2009. Our assessments of the risk of bias are presented in Figs 3 and 4.
Despite varying geographic sites, the patient populations of these studies included adults with
hematologic malignancy undergoing intensive chemotherapy or HSCT
Included studies consistently defined empirical antifungal therapy as the initiation of anti-
fungal drugs after a defined number of consecutive days with persistent febrile neutropenia.
However, there was significant variation in the trigger (clinical symptoms, chest imaging,
galactomannan, PCR, traditional fungal cultures) for starting antifungal therapy in the pre-
emptive study groups, presenting another type of bias. The majority (9 of 10) incorporated
chest imaging findings into the trigger. The remaining study [34] used a positive fungal PCR as
the only trigger for initiating pre-emptive therapy. Fungal biomarkers, either galactomannan
or fungal PCR, were also consistently employed in all studies as part of the pre-emptive
approach, although there was variability in whether one or both were applied [26,31].
Of seven studies that measured and reported IFD detection, two found a significantly higher
rate of IFD detection in the pre-emptive therapy group (Table 2) [26, 31]. In the trial by Morri-
sey and colleagues, for example, IFD detection rate was 4.1% with empirical and 19.5% with
pre-emptive management. Compared to studies that did not find a significant difference in
IFD detection between the two antifungal strategies, those that did were better powered to
identify such a difference with larger sample sizes. Pooled RR for IFD detection comparing
pre-emptive to empirical strategies was 1.70 (95%CI 1.12–2.57) using a M-H fixed-effects
Empirical versus Preemptive Antifungals in High-Risk Neutropenic Fever
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model and 1.47 (95%CI 0.55–3.96) with a D-L random-effects model, suggesting potentially
increased IFD detection with pre-emptive strategies (Fig 5). Of note, there was significant het-
erogeneity between studies in IFD detection (Cochran’s Q p = 0.008; I2 = 71.3%; τ2 = 0.810).
Of the five studies reporting IFD-related mortality, none found a significant difference with
empirical versus pre-emptive management (Fig 6) and there was no difference in IFD-related
mortality pooled RR comparing the two groups (M-H RR 0.85, 95% CI 0.45–1.62; D-L RR
0.82, 95%CI 0.36–1.87). We found no significant heterogeneity among individual study RRs of
IFD-related mortality (Cochran’s Q p = 0.306; I2 = 17.0%; τ2 = 0.132). While one study identi-
fied a significant difference in overall mortality between pre-emptive and empirical strategies,
Fig 2. PRISMA Flow Diagram of studies included in systematic review andmeta-analysis.
doi:10.1371/journal.pone.0140930.g002
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Table 1. Summary of studies comparing empirical versus pre-emptive antifungal therapy in high-risk febrile neutropenic patients.
Study Design Population Study
Period
Empirical
Protocol
Pre-emptive
Protocol
Diagnostic
Testing
Antifungal Primary
Endpoint
Morrissey
2013 [31]
Open-label
randomized
controlled trial
AUSTRALIA
(n = 240) Patients
18 years
undergoing
allogeneic HSCT
or intensive
chemotherapy for
AML or ALL
9/
2005-
11/
2009
Antifungal
drug started
after
persistent
fever for 3
consecutive
days
Antifungal drug
started after a
single positive
GM, single
positive PCR
result, or serially
negative results in
patients with
characteristic
chest CT ﬁndings
GM 2x/week;
Nested
Aspergillus
PCR 2x/week;
Chest CT after
positive GM or
PCR
AmB, L-AmB,
Voriconazole
per Australian
consensus
guidelines
Antifungal
treatment
within 26
weeks of
enrollment
Cordonnier
2009 [26]
Open-label
randomized
non-inferiority
trial
FRANCE
(n = 293) Patients
18 years with
hematological
malignancy
scheduled for
chemotherapy or
autologous HSCT
expected to have
prolonged
neutropenia
4/
2003–
2/2006
Antifungal
drug started
after 4 days of
persistent
fever or
recurrent fever
after 4 days
Antifungal drug
started after 4
days of persistent
fever with clinical/
imaging-
documented
pneumonia or
acute sinusitis,
mucositis, septic
shock, skin lesion
suggesting IFD,
unexplained CNS
symptoms,
periorbital
inﬂammation,
splenic or hepatic
abscess, severe
diarrhea,
Aspergillus
colonization or
positive serum GM
GM 2x/week;
Chest X-ray
followed by
Chest CT
AmB, L-AmB,
Caspofungin,
Voriconazole
Difference in
mortality 14
days after
recovery of
neutropenia or
after 60 days of
study inclusion
Hebart
2009 [29]
Open-label
randomized
controlled trial
EUROPE
(n = 403) Patients
undergoing
allogeneic HSCT
without
amphotericin
allergy or existing
IFD
7/
1998-
6/2001
Antifungal
drug started
after  5 days
of febrile
neutropenia or
detection of
pulmonary
inﬁltrate
Antifungal drug
started after 1
positive PCR
result or detection
of pulmonary
inﬁltrate
Non-nested
Aspergillus and
Candida PCR;
Chest CT;
Abdominal CT;
Blood cultures
L-AmB IFD Detection
100 days after
transplant
Blennow
2010 [34]
Open-label
randomized
trial
SWEDEN (n = 99)
Patients
undergoing
RIC-HSCT without
hypersensitivity to
AmB
4/
2002-
11/
2006
No
intervention
Positive PCR
randomized to
AmB, patients with
persistent fever
regardless of PCR
result
Non-nested
Aspergillus and
Candida whole
blood PCR
L-AmB 100 day
survival; 1 year
IFD detection;
IFD risk factors
Tan 2011
[35]
Open-label
randomized
trial
SINGAPORE
(n = 47, NE = 52)
Patients  12
years with
hematologic
malignancy
undergoing
intensive
consolidative
chemotherapy or
HSCT
6/
2006-
10/
2007
Standard of
care
according to
institutional
guidelines,
empirical
antibiotics
allowed if
indicated
Antifungals started
after two positive
GM x2 and/or
chest CT
suggestive of IFD
GM 2x/week;
Chest CT after
positive GM
Caspofungin,
L-AmB, AmB,
Voriconazole
Proven/
probable IFD
(Continued)
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with decreased mortality with the pre-emptive strategy (RR 0.16, 95%CI 0.04–0.71)[36], there
was no difference in the pooled RR of overall mortality between the two groups (M-H RR 0.99,
95%CI 0.70–1.40; D-L RR 0.95, 95%CI 0.46–1.99) (Fig 7). Of note, there was significant hetero-
geneity in overall mortality rates (Cochran’s Q p = 0.05; I2 = 61.9%; τ2 = 0.328).
Five of seven studies assessing antifungal use found a significant decrease in antifungal use
in the pre-emptive therapy group (Table 3, Fig 8) [25,26,28–30]. For example, in the Cordon-
nier trial, 61.3% of patients on the empirical strategy arm received antifungals compared to
39.2% of patients on the pre-emptive strategy arm. Furthermore, among patients who did
receive antifungals, the duration of antifungal use was shorter in the pre-emptive group [26],
Table 1. (Continued)
Study Design Population Study
Period
Empirical
Protocol
Pre-emptive
Protocol
Diagnostic
Testing
Antifungal Primary
Endpoint
Aguilar-
Guisado
2010 [36]
Prospective
interventional
study
SPAIN (n = 66)
Patients  16
years post-
chemotherapy or
post-HSCT
11/
2002-
2/2005
Antifungal
drug started in
patients with
sepsis, or
identiﬁed foci
of infection, or
per clinical
discretion in
high-risk
patients
If no identiﬁed foci
of infection, chest
CT, abdominal
ultrasound, and
blood cultures with
initiation of
antifungal therapy
if diagnostic work-
up positive
Chest X-ray;
Blood cultures;
Chest CT in
those with
abnormal Chest
X-ray;
Abdominal
ultrasound
AmB,
Voriconazole,
Caspofungin
IFD detection;
IFD-related
mortality
Oshima
2007 [30]
Retrospective
chart review
JAPAN (n = 124)
Adult patients who
underwent
allogeneic HSCT
at a university
hospital
9/
2002–
12/
2005
At the
discretion of
the attending
Antifungal drug
started after  7
days of persistent
or recurrent febrile
neutropenia,
positive GM, and/
or inﬁltrates or
nodules on chest
X-ray or CT
GM; Beta-D
glucan
AmB,
Micafungin,
Itraconazole,
Voriconazole
Development
of proven/
probable early
invasive
aspergillosis
Girmenia
2010 [28]
Prospective
feasibility
study
ITALY (n = 146,
NE = 220)
Patients  18
years with
hematologic
malignancy who
underwent
chemotherapy or
autologous HSCT
and developed
neutropenia 7
days
3/
2006–
2/2007
— Antifungal drug
started after
positive blood
culture, GM, and/
or characteristic
chest CT ﬁndings
3 blood
cultures; GM
for 3
consecutive
days; Chest
CT; Other
microbiologic or
clinical
examinations
as indicated
Voriconazole,
AmB, L-AmB,
Caspofungin,
Fluconazole
Rate of
patients
receiving
antifungal
therapy
Maertens
2005 [37]
Prospective
feasibility
study
BELGIUM (n = 88,
NE = 136)
Patients 16
years receiving
chemotherapy for
acute leukemia/
MDS or
undergoing
myeloablative
allogenic HSCT
1/
2003-
1/2004
— Antifungal
treatment after 2
+ consecutive
positive
galactomannan or
with CT ﬁndings
suggestive of IFD
GM; Chest X-
ray 1-2x/week;
Blood, sputum,
urine, stool
cultures
L-AmB Rate of
antifungal use;
IFD cases
AML: Acute myelogenous leukemia, ALL: Acute lymphocytic leukemia, NE: Febrile neutropenic episodes, IFD: invasive fungal disease, HSCT:
Hematopoietic stem-cell transplantation, RIC: reduced intensity conditioning, GM: Aspergillus galactomannan, CT: Computed tomography scan, PCR:
Polymerase chain reaction, AmB: amphotericin B deoxycholate, L-AmB: liposomal amphotericin B
doi:10.1371/journal.pone.0140930.t001
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Table 2. Comparison of IFD-related outcomes in empiric versus pre-emptive antifungal therapy in high-risk neutropenic patients.
IFD Detection IFD-related Mortality Overall Mortality
Study RR (95%CI) Empiric
(%)
Pre-emptive
(%)
RR (95%CI) Empiric
(%)
Pre-emptive
(%)
RR (95%
CI)
Empiric
(%)
Pre-emptive
(%)
Morrissey 2013 [31] 4.76 (1.87–
12.10)
4.1 (5/
122)
19.5 (23/
118)
0.86 (0.27–
2.75)
4.9 (6/
122)
4.2 (5/118) 1.55 (0.66–
3.66)
6.6 (8/122) 10.2 (12/
118)
Cordonnier 2009
[26]
3.41 (1.14–
10.21)
2.7 (4/
150)
9.1 (13/143) 7.34 (0.38–
140.86)
0.0 (0/
150)
2.1 (3/143) 1.84 (0.55–
6.14)
2.7 (4/150) 4.9 (7/143)
Hebart 2009 [29] 0.99 (0.52–
1.91)
8.1 (17/
207)
8.2 (16/196) 0.82 (0.36–
1.87)
4.8 (10/
207)
3.6 (7/196) 0.99 (0.64–
1.55)
16.4 (34/
207)
16.3 (32/
196)
Blennow 2010 [34] — 0.0 (0/8) 7.7 (1/13) — — — — — —
Tan 2011 [35] 0.62 (0.11–
3.39)
12.0 (3/
25)
7.4 (2/27) — — — — — —
Aguilar-Guisado
2010 [36]
0.09 (0.01–
1.75)
11.5 (3/
26)
0.0 (0/40) 0.13 (0.01–
2.64)
8.0 (2/26) 0.0 (0/40) 0.16 (0.04–
0.71)
30.7 (8/26) 5.0 (2/40)
Oshima 2007 [30] — 0.0 (0/13) 3.3 (2/60) — 0.0 (0/13) 0.0 (0/60) — — —
Girmenia 2010 [28] — — — — — — — — —
Maertens 2005 [37] — — — — — — — — —
M-H RR (95%CI) 1.70 (1.12–2.57) 0.85 (0.45–1.62) 0.99 (0.70–1.40)
D-L RR (95%CI) 1.47 (0.55–3.96) 0.82 (0.36–1.87) 0.95 (0.46–1.99)
Q = 13.90 (df = 4), p = 0.01 Q = 3.62 (df = 3), p = 0.31 Q = 7.88 (df = 3), p = 0.05
Heterogeneity I2 = 71.3% I2 = 17.0% I2 = 61.9%
Between study τ2 = 0.81 Between study τ2 = 0.13 Between study τ2 = 0.33
RR: relative risk, CI: conﬁdence interval, IFD: invasive fungal disease, RR: relative risk, CI: conﬁdence interval, M-H: Mantel-Haenszel ﬁxed effects model,
D-L: Dersimonian-Laird random effects models,—data unavailable and cannot be derived from this study
doi:10.1371/journal.pone.0140930.t002
Table 3. Comparison of antifungal use in empiric versus pre-emptive antifungal therapy in high-risk neutropenic patients.
Antifungal Use Antifungal Duration (mean)
Study RR (95%CI) Empiric (%) Pre-emptive (%) Empiric (%) Pre-emptive (%) p
Morrissey 2013 [31] 0.48 (0.29–0.79) 30.3 (39/122) 23.7 (18/118) — — —
Cordonnier 2009 [26] 0.64 (0.50–0.81) 61.3 (92/150) 39.2 (56/143) 7.0 days 4.5 days <0.01
Hebart 2009 [29] 1.56 (1.25–1.93) 36.7 (76/207) 57.1 (112/196) 84.2% (64/76) <30 days 79.5% (89/112) <30 days NS
Blennow 2010 [34] — — — — — —
Tan 2011 [35] 0.76 (0.38–1.51) 44.0 (11/25) 33.3 (9/27) — — —
Aguilar-Guisado 2010 [36] — — — — — —
Oshima 2007 [30] 0.08 (0.03–0.19) 100.0 (13/13) 6.7(4/60) — — —
Girmenia 2010 [28] 0.57 (0.42–0.77) 52.8 (84/220) 30.1 (48/220) — — —
Maertens 2005 [37] 0.22 (0.11–0.43) 35.0 (41/117) 7.7 (9/117) — — —
M-H RR (95%CI) 0.72 (0.63–0.81) —
D-L RR (95%CI) 0.48 (0.27–0.85) —
Q = 91.01 (df = 6), p 0.01
Heterogeneity I2 = 93.4% —
Between study τ2 = 0.503
RR: relative risk, CI: conﬁdence interval, IFD: invasive fungal disease, RR: relative risk, CI: conﬁdence interval, M-H: Mantel-Haenszel ﬁxed effects model,
D-L: Dersimonian-Laird random effects models,—data unavailable and cannot be derived from this study
doi:10.1371/journal.pone.0140930.t003
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with an average antifungal duration of 7.0–11.2 days in the empirical group and 4.5–8.7 days in
the pre-emptive group. Notably, there was no difference in antifungal drug toxicity, either
renal or hepatic, or in discontinuation of antifungal therapy between the two groups in any of
the studies. The pooled RR of antifungal use was significantly lower using pre-emptive com-
pared to empirical strategies (M-H RR 0.72, 95%CI 0.63–0.81; D-L 0.48, 95%CI 0.27–0.85). Of
note, we detected statistical heterogeneity among individual RRs of antifungal drug use
(Cochran’s Q p<0.001; I2 = 93.4%; τ2 = 0.503).
Overall, the existing literature demonstrates that pre-emptive diagnostic-test driven
approaches may increase IFD detection without an increase in IFD-related or overall mortality,
compared to empirical therapy. The majority of studies showed a reduction in the proportion
of patients receiving antifungals and duration of antifungal exposure using a pre-emptive
strategy.
Cost Comparison Model
Tables 4 and 5 outline clinical and cost parameters incorporated into the cost-comparison
analysis, respectively, and Table 6 summarizes the results of this model. Assuming similar
Fig 3. Risk of bias in randomized studies as assessed by the Cochrane Collaboration’s “Risk of Bias” tool.
doi:10.1371/journal.pone.0140930.g003
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diagnostic strategies and otherwise similar baseline costs, the pre-emptive approach cost $325
less than the empirical approach overall ($2053.50 pre-emptive vs. $2378.00 empirical) per
febrile neutropenic episode. During the empirical or pre-emptive period alone, empirical ther-
apy cost $594 more than pre-emptive management ($1,209 pre-emptive vs. $1,803 empirical)
per FN episode, due to a greater rate and duration of antifungal drug exposure using the empir-
ical strategy.
Sensitivity Analysis
Our cost estimates did not change when we derived model parameters only from the most
robust randomized controlled trials of empirical versus preemptive antifungal therapy [26,31].
See supplementary material for plug-in model allowing for base case parameter adjustments
(S1 Model).
Probabilistic sensitivity analysis using 95% confidence intervals derived from our meta-
analysis for relative risks of IFD detection and antifungal use resulted in 95% credible intervals
for the cost of pre-emptive therapy being $291.88 less to $418.65 more costly than empirical
therapy overall, and pre-emptive therapy being $269.00 less to $106.33 more costly than empir-
ical therapy prior to IFD detection. With one-way sensitivity analysis, with the RR of IFD
detection comparing pre-emptive and empirical groups increased to a threshold of RR of 2.03,
pre-emptive therapy became the more costly strategy. As long as the proportion of patients in
the pre-emptive group receiving antifungal treatment was less than or equal to the proportion
Fig 4. Risk of bias in non-randomized studies as assessed by the Newcastle-Ottawa Scale.
doi:10.1371/journal.pone.0140930.g004
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of people being treated in the empirical therapy group, empirical therapy was always the more
costly strategy.
Our results were sensitive to changes in the diagnostic testing strategy, antifungal drug
costs, antifungal duration, and ratios of incident IFD diagnoses and antifungal use between the
pre-emptive and empirical groups. For the diagnostic testing strategy, if the pre-emptive group
received an additional chest CT scan per FN episode, the two strategies were nearly equivalent
in cost with the empirical group being only $90 more costly overall per FN episode.
With regards to antifungal drugs, the pre-emptive strategy became equivalent to empirical
therapy (more costly by $12 per patient) using the most conservative estimate of drug costs
(voriconazole) at $49 per day. In contrast, using a more expensive drug regimen of liposomal
amphotericin B ($785 per day) in the pre-IFD diagnosis period and posaconazole ($172 per
day) in the post-IFD diagnosis period made empirical therapy the even more costly strategy by
$1,453 per FN episode. At a threshold pre-IFD diagnosis antifungal drug cost of $111 per day
and post-IFD diagnosis antifungal drug cost of $221 per day, the two strategies were equivalent
in cost. At an antifungal treatment duration threshold of less than 185 days following incident
IFD diagnosis, pre-emptive therapy became the more costly strategy.
Fig 5. Forest plot of pooled relative risk of IFD detection comparing pre-emptive to empirical strategies.
doi:10.1371/journal.pone.0140930.g005
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Discussion
This study provides the first systematic analysis of available evidence comparing empirical and
pre-emptive antifungal therapy strategies among hematologic malignancy or HSCT patients
with high-risk FN. Overall, pre-emptive therapy was associated with decreased antifungal treat-
ment rates and duration and diagnostic-test driven increased IFD detection without an
increase in IFD-related mortality. We incorporated these composite estimates in a cost com-
parison model and found a state of economic equipoise between empirical and pre-emptive
antifungal therapy, slightly favoring pre-emptive therapy as the less costly strategy by $325 per
FN episode, but influenced by relatively small changes in the cost of antifungal therapy and
diagnostic testing. However, overall costs incorporating treatment for proven and probable
IFD were consistently higher with pre-emptive therapy, largely due to the increased diagnosis
of incident IFD and the cost of antifungal treatment for diagnosed IFD cases in this group.
The influence of diagnostic testing for IFD is evident in our results. Pre-emptive approaches
in the studies we examined varied significantly in fungal biomarker and imaging use. In partic-
ular, studies we reviewed employed varying combinations of galactomannan, beta-D-glucan,
and fungal PCR. Of these, serum galactomannan was the most common biomarker trigger for
starting pre-emptive antifungal therapy. Fungal PCR was also used in conjunction with galac-
tomannan in some of these studies, though this assay is subject to variations in internal and
external validity [38]. Still, a recent study showed that galactomannan combined with
Fig 6. Forest plot of pooled relative risk of IFD-associated mortality comparing pre-emptive to empirical strategies.
doi:10.1371/journal.pone.0140930.g006
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Aspergillus PCR may lead to earlier diagnosis of invasive aspergillosis, lower IFD detection,
and reduced antifungal use compared to galactomannan alone [39].
Also important to consider is the clinical and economic significance of IFD diagnoses in the
setting of augmented diagnostic surveillance. Higher IFD detection without a corresponding
increase in IFD-related mortality with pre-emptive therapy likely reflects the sensitivity of
serial, systematically assessed fungal biomarkers and chest imaging for IFD, with initiation of
antifungal therapy when there is relatively limited extent of fungal disease. However, higher
rate of IFD identification with the pre-emptive strategy led to increased antifungal treatment
and overall costs compared to the empirical group.
This work also highlights the heterogeneity of antifungal drug treatment for incident IFD.
Pre-emptive management led to an overall reduction in antifungal use and duration. However,
the cost of specific antifungal agents influenced which approach was more costly. This is partic-
ularly relevant given institutional and regional variability in IFD epidemiology, antifungal drug
susceptibility, and clinical management of patients with prolonged FN. Specifically, combina-
tion antifungal therapy is increasingly used in refractory cases with a recent study suggesting
potentially increased efficacy in the treatment of early invasive aspergillosis [40].
Limitations of our systematic review and cost comparison are largely intrinsic to the avail-
able literature comparing empirical and pre-emptive antifungal therapy in FN patients. Many
of the studies we incorporated into our estimates of IFD detection, IFD-related mortality,
Fig 7. Forest plot of pooled relative risk of overall mortality comparing pre-emptive to empirical strategies.
doi:10.1371/journal.pone.0140930.g007
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antifungal use, and antifungal duration were small, observational studies [27,34]. Together,
works we included encompassed heterogeneous patient groups with varying IFD prevalence,
underlying immune deficits, antifungal prophylaxis rates, definitions of empirical and preemp-
tive therapy, diagnostic testing strategies, and treatment regimens for incident IFD. To address
this issue in part, we conducted tests of heterogeneity and, finding evidence of heterogeneity in
some of these parameters between studies, used mixed effect models to estimate pooled relative
risks. Sensitivity analysis using parameters derived from only the largest, most robust compari-
sons of empirical and pre-emptive antifungal therapy also did not change the outcome of our
cost comparison model.
While simple, our cost comparison model incorporated key differences in antifungal use,
diagnostic testing, and clinical outcomes driving cost differences between the two strategies.
Compared to the two existing published cost-effectiveness studies comparing empirical and
pre-emptive antifungal therapy in FN [22,23], our model parameters are derived from compos-
ite estimates using all available data comparing these two strategies. In contrast, Martín-Peña
et al used parameters derived solely from two small observational studies and assumed signifi-
cant differences in key patient characteristics and outcomes. While they found that pre-emp-
tive therapy was 2.6% more effective and 33% less costly, their results may have limited
Fig 8. Forest plot of pooled relative risk of antifungal drug use comparing pre-emptive to empirical strategies.
doi:10.1371/journal.pone.0140930.g008
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Table 4. Clinical parameters incorporated into cost comparisonmodel.
Clinical Data Value Reference
Duration of Neutropenia (days) 18 days [26]
IFD detection
Empirical Therapy 0.068 Table 2
Pre-emptive Therapy 0.100 Table 2
Antifungal Use Data
Ratio of Pre-IFD diagnosis antifungal use 0.48 Table 3
Ratio of Pre-IFD diagnosis antifungal duration 0.64 Table 3
Empirical Therapy
Proportion with empirical antifungal use 0.50 Table 3
Duration of empirical antifungal use (days) 7.0 [26]
Pre-emptive Therapy
Proportion with pre-emptive antifungal use 0.24 Calculated a
Duration of pre-emptive antifungal use (days) 4.5 Calculated b
Duration of antifungal treatment 84 days [24]
a[Proportion with antifungal treatment (empirical)] x [Ratio of antifungal treatment]
b[Antifungal duration (empirical)] x [Ratio of antifungal duration]
doi:10.1371/journal.pone.0140930.t004
Table 5. Cost parameters incorporated into cost comparisonmodel.
Diagnostic Testing Costs Value ($) Reference
Diagnostic Test
Chest CT scan 414 [32]
Galactomannan test 133 BWH/DFCIa Laboratory
Cost of Diagnostic Testing (per patient per week of persistent febrile neutropenia >4 days)
Empirical Therapy 2 galactomannan/week and 1 CT scan 946 [26]
Pre-emptive Therapy 2 galactomannan/week and 1 CT scan 946 Expert opinion
Antifungal Treatment Costs
Pre-IFD Diagnosis Antifungals (daily per 65kg patient) (90% mica, 5% vori, 5% L-AmB) 244 Expert opinion
Incident IFD Treatment Antifungals (daily per 65kg patient) (85% vori, 5% posa, 5% L-AmB, 5% mica) 101 Expert opinion
Liposomal amphotericin B (L-AmB) 3mg/kg at $196.25 per 50mg vial 785 [33]
Micafungin (mica) 224 [33]
Voriconazole (vori) 2x200mg tablets 49 [33]
Posaconazole (posa) 800mg/day 172 [33]
aBrigham and Women’s Hospital/Dana-Farber Cancer Institute
doi:10.1371/journal.pone.0140930.t005
Table 6. Results of the cost-comparisonmodela.
Strategy Pre-IFD Diagnosis Antifungalsb Incident IFD Treatment Antifungalsc Total Costd ($)
Empirical Therapy 858 574 2378
Pre-emptive Therapy 263 844 2053
aAll costs are per patient.
b[Daily cost of pre-IFD diagnosis antifungals] x [Proportion with pre-IFD diagnosis antifungals] x [Duration of pre-IFD diagnosis antifungals]
c[Daily cost of incident IFD treatment antifungals] x [IFD detection] x [Duration of incident IFD treatment antifungals]
d[Cost of diagnostic testing] + [Cost of pre-IFD diagnosis antifungals] + [Cost of incident IFD treatment antifungals]
doi:10.1371/journal.pone.0140930.t006
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generalizability and validity [22]. Similarly, Barnes et al constructed a model that made several
assumptions (most notably, differences in IFD-associated mortality, overall mortality, and
antifungal toxicity between empirical and pre-emptive strategies) that are not supported by
current literature examining empirical versus pre-emptive antifungal therapy [23,26,29,30,31].
Overall, we show that a diagnostic test-guided pre-emptive approach to antifungal manage-
ment in FN is a clinically and economically reasonable alternative to fever-based empirical
therapy. Forthcoming results of the EORTC randomized trial of caspofungin for empirical ver-
sus diagnostic-guided pre-emptive antifungal therapy in patients with acute myeloid leukemia
or myelodysplastic syndrome and the subsequent economic analysis should help further eluci-
date some of these issues substantially [41]. Our findings also emphasize the need for ongoing
investigation of the utility and cost of existing fungal diagnostic tests and the development of
more efficient, accurate, and cost-effective diagnostic strategies to shift economic momentum
towards more rational pre-emptive therapeutic approaches.
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